Last reviewed · How we verify
LAIV H7N3
LAIV H7N3 is a Biologic drug developed by PATH. It is currently in Phase 1 development. Also known as: A/17/mallard/Netherlands/00/95 (H7N3).
LAIV H7N3 is a type of live attenuated influenza vaccine. It has been studied in clinical trials for its safety and immune response in healthy adults, particularly in relation to its potential to prime the immune system for subsequent responses to other influenza viruses.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LAIV H7N3 |
|---|---|
| Also known as | A/17/mallard/Netherlands/00/95 (H7N3) |
| Sponsor | PATH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety Trial of Live Attenuated Influenza (H7N3) Vaccine (PHASE1)
- Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine (PHASE1)
- Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAIV H7N3 CI brief — competitive landscape report
- LAIV H7N3 updates RSS · CI watch RSS
- PATH portfolio CI
Frequently asked questions about LAIV H7N3
What is LAIV H7N3?
Who makes LAIV H7N3?
Is LAIV H7N3 also known as anything else?
What development phase is LAIV H7N3 in?
Related
- Manufacturer: PATH — full pipeline
- Also known as: A/17/mallard/Netherlands/00/95 (H7N3)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing